1. Home
  2. LIXT vs ACON Comparison

LIXT vs ACON Comparison

Compare LIXT & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$4.11

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Logo Aclarion Inc.

ACON

Aclarion Inc.

HOLD

Current Price

$6.44

Market Cap

4.4M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIXT
ACON
Founded
2005
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
25.4M
4.4M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
LIXT
ACON
Price
$4.11
$6.44
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$23.00
AVG Volume (30 Days)
88.8K
59.9K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$67,483.00
Revenue This Year
N/A
$145.39
Revenue Next Year
N/A
$145.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.91
52 Week Low
$0.64
$5.55
52 Week High
$6.26
$3,499.49

Technical Indicators

Market Signals
Indicator
LIXT
ACON
Relative Strength Index (RSI) 44.10 48.03
Support Level $4.01 $5.71
Resistance Level $4.40 $6.89
Average True Range (ATR) 0.39 0.61
MACD -0.00 0.06
Stochastic Oscillator 40.94 35.04

Price Performance

Historical Comparison
LIXT
ACON

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Share on Social Networks: